The Effects of Botulinum Toxin A Injections on Patients with Radiogenic Lower Urinary Tract Symptoms
Toxins · 2025
DOI: 10.3390/toxins17040200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Anke K Jaekel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Lower Urinary Tract Symptoms, Neuromuscular Agents, Radiation Injuries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open Access Publication Fund of the University of Bonn, German charity fund ‘Förderverein zur Kontinenzforschung und Kontinenzaufklärung e. V.’.
Abstract (Originalsprache)
Botulinum toxin A (BTX-A) injection into the detrusor vesicae is an established therapy for neurogenic lower urinary tract dysfunction as well as idiopathic overactive bladder. Pelvic radiotherapy causes comparable lower urinary tract symptoms (LUTS) in a third of radiated patients. Little is known about the effects of BTX-A injections into the detrusor vesicae in the management of radiogenic LUTS. Our aim was to assess the effect of BTX A injections on these symptoms and related quality of life. Material and Methods: In total, 28 patients with BTX-A injections for radiogenic LUTS were assessed retrospectively. We analyzed symptoms recorded in bladder diaries, the results of quality-of-life questionnaires (ICIQ-LUTSqol), and urodynamic studies (UDS) before and after BTX-A injections.
Results
A significant reduction in daily micturition frequency, nocturia, and pad consumption was demonstrated in the overall cohort and in gender-related subgroup analysis. There was a significant decrease in the ICIQ-LUTSqol independent of gender or BTX-A units. For UDS maximum cystometric bladder capacity (188.0 vs. 258.2 mL, p = 0.043), micturition volume (138.2 vs. 216.7 mL, p = 0.018), and first desire to void (98.2 vs. 171.2 mL, p = 0.042) was significantly improved. No side effects of the toxin injection or urinary retention were observed.
Conclusions
Intradetrusor injection therapy with BTX-A could represent a safe and effective therapeutic option for radiogenic LUTS with increasing quality of life, reductions in symptoms, and the improvement of urodynamic parameters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany.
- Department of Neuro-Urology, Johanniter Neurological Rehabilitation Center Godeshoehe GmbH, 53177 Bonn, Germany.
- Clinic for Urology and Pediatric Urology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
ORCID-Profile: Anke K Jaekel
Förderung
- Open Access Publication Fund of the University of Bonn
- German charity fund ‘Förderverein zur Kontinenzforschung und Kontinenzaufklärung e. V.’
Zitieren
APA
Jaekel, A. K., Brüggemann, A. C., Bitter, J., Knappe, F., Kirschner-Hermanns, R., & Knüpfer, S. C. (2025). The Effects of Botulinum Toxin A Injections on Patients with Radiogenic Lower Urinary Tract Symptoms. Toxins. https://doi.org/10.3390/toxins17040200
Vancouver
Jaekel AK, Brüggemann AC, Bitter J, Knappe F, Kirschner-Hermanns R, Knüpfer SC. The Effects of Botulinum Toxin A Injections on Patients with Radiogenic Lower Urinary Tract Symptoms. Toxins. 2025. doi:10.3390/toxins17040200
BibTeX
@article{Jaekel2025,
author = {Jaekel, Anke K and Brüggemann, Ann-Christin and Bitter, John and Knappe, Franziska and Kirschner-Hermanns, Ruth and Knüpfer, Stephanie C},
title = {The Effects of Botulinum Toxin A Injections on Patients with Radiogenic Lower Urinary Tract Symptoms},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17040200}
}
EUVIMED